Linked Data API

Show Search Form

Search Results

386886
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Bone Marrow Disorders more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL995 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL996 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.197Zmore like thismore than 2015-07-14T15:34:29.197Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386888
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386467
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Pancreatic Cancer: Nurses more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what steps they are taking to ensure that all pancreatic cancer patients have access to a clinical nurse specialist. more like this
star this property tabling member printed
Lord Aberdare more like this
star this property uin HL962 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
unstar this property answer text <p>NHS England has a published service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>Patients being treated at cancer units should have access to an upper gastrointestinal cancer nurse. All district general hospitals should have such a person in post. If the patient is transferred to a cancer centre they should then have access to a pancreatic nurse specialist. This person should see every patient and become their key worker.</p><p> </p><p> </p><p> </p><p>Patients with suspected pancreatic cancer are usually first investigated by an ultrasound scan. If this shows biliary dilatation, or anything else suspicious, the patient should then be sent for a pancreas protocol computerised tomography scan which is the best investigation for identifying pancreatic cancer.</p><p> </p><p> </p><p> </p><p>Increasing the capacity of diagnostic and imaging services is clearly recognised as a priority for the National Health Service and it is has been raised as a key issue by the independent Cancer Taskforce, as well as by the Cancer Waiting Times Taskforce. We expect a new cancer strategy to be published this summer which will set out the strategy for the system for the next five years and will include consideration of the whole cancer pathway, including the capacity of diagnostic services.</p><p> </p><p> </p><p> </p><p>In addition, NHS England is testing various approaches to new models of care which could potentially deliver improved access to diagnostic services for cancer patients, including those with pancreatic cancer.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL963 more like this
star this property question first answered
less than 2015-07-09T12:43:47.243Zmore like thismore than 2015-07-09T12:43:47.243Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
3898
unstar this property label Biography information for Lord Aberdare more like this
386468
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Pancreatic Cancer: Tomography more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what plans they have to increase the capacity of imaging services available to pancreatic cancer patients across the National Health Service, including computerised tomography scans. more like this
star this property tabling member printed
Lord Aberdare more like this
star this property uin HL963 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
unstar this property answer text <p>NHS England has a published service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>Patients being treated at cancer units should have access to an upper gastrointestinal cancer nurse. All district general hospitals should have such a person in post. If the patient is transferred to a cancer centre they should then have access to a pancreatic nurse specialist. This person should see every patient and become their key worker.</p><p> </p><p> </p><p> </p><p>Patients with suspected pancreatic cancer are usually first investigated by an ultrasound scan. If this shows biliary dilatation, or anything else suspicious, the patient should then be sent for a pancreas protocol computerised tomography scan which is the best investigation for identifying pancreatic cancer.</p><p> </p><p> </p><p> </p><p>Increasing the capacity of diagnostic and imaging services is clearly recognised as a priority for the National Health Service and it is has been raised as a key issue by the independent Cancer Taskforce, as well as by the Cancer Waiting Times Taskforce. We expect a new cancer strategy to be published this summer which will set out the strategy for the system for the next five years and will include consideration of the whole cancer pathway, including the capacity of diagnostic services.</p><p> </p><p> </p><p> </p><p>In addition, NHS England is testing various approaches to new models of care which could potentially deliver improved access to diagnostic services for cancer patients, including those with pancreatic cancer.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL962 more like this
star this property question first answered
less than 2015-07-09T12:43:47.337Zmore like thismore than 2015-07-09T12:43:47.337Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
3898
unstar this property label Biography information for Lord Aberdare more like this
76618
star this property registered interest false more like this
star this property date less than 2014-07-09more like thismore than 2014-07-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Neurofibromatosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to develop a national service framework for neurofibromatosis Type 1 sufferers. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL960 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-07-14more like thismore than 2014-07-14
unstar this property answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p>
star this property answering member printed Earl Howe more like this
star this property grouped question UIN
HL961 more like this
HL962 more like this
star this property question first answered
less than 2014-07-14T16:18:37.8359721Zmore like thismore than 2014-07-14T16:18:37.8359721Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
76619
star this property registered interest false more like this
star this property date less than 2014-07-09more like thismore than 2014-07-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Neurofibromatosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how they will ensure a co-ordinated response at local level for neurofibromatosis Type 1 sufferers. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL961 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-07-14more like thismore than 2014-07-14
unstar this property answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p>
star this property answering member printed Earl Howe more like this
star this property grouped question UIN
HL960 more like this
HL962 more like this
star this property question first answered
less than 2014-07-14T16:18:38.4851111Zmore like thismore than 2014-07-14T16:18:38.4851111Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
76620
star this property registered interest false more like this
star this property date less than 2014-07-09more like thismore than 2014-07-09
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Neurofibromatosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what is the scale of neurofibromatosis Type 1 in the United Kingdom. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL962 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-07-14more like thismore than 2014-07-14
unstar this property answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p>
star this property answering member printed Earl Howe more like this
star this property grouped question UIN
HL960 more like this
HL961 more like this
star this property question first answered
less than 2014-07-14T16:18:38.5632682Zmore like thismore than 2014-07-14T16:18:38.5632682Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
347226
star this property registered interest false more like this
star this property date less than 2015-05-28more like thismore than 2015-05-28
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Clinical Commissioning Groups: Staffordshire more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the conclusion drawn in the Staffordshire Distressed Health Economy report by KPMG that there is a lack of collaborative working across the six Clinical Commissioning Groups in Staffordshire to maximise leadership capabilities. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL90 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-06-09more like thismore than 2015-06-09
unstar this property answer text <p>NHS England has identified the Staffordshire clinical commissioning groups (CCGs) as high risk, and as such is monitoring their performance on a monthly basis with a full quarterly review of finance and performance. NHS England increases the intensity of performance reviews where there are significant shortfalls. This includes weekly meetings with CCGs where appropriate.</p><p> </p><p> </p><p> </p><p>Collaborative working relationships are a critical factor in securing sustainable services in any local health economy. The Commissioning Congress has been set up in Staffordshire to bring together both CCGs and local authority commissioners. The Congress will lead the Transformation Strategy which will drive the service redesign of the Staffordshire Health and Social Care economy to secure financial and clinically sustainable services in the long term. The Congress will engage with local providers in developing these plans to ensure that there is a single five-year plan for the local health economy. This work will lead to a full public consultation on those services during the autumn of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>The Congress brings together the combined skills, knowledge and expertise of commissioners to work the provider sector on defining the range, scale and scope of services changes to ensure Staffordshire is both clinically and financially sustainable in the long term.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL88 more like this
HL91 more like this
HL92 more like this
HL93 more like this
star this property question first answered
less than 2015-06-09T12:42:46.893Zmore like thismore than 2015-06-09T12:42:46.893Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
347224
star this property registered interest false more like this
star this property date less than 2015-05-28more like thismore than 2015-05-28
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health remove filter
star this property answering dept sort name Health more like this
star this property hansard heading Health Services: Staffordshire more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what action they are taking to ensure the viability of comprehensive patient services in the Staffordshire local health economy. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL88 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-06-09more like thismore than 2015-06-09
unstar this property answer text <p>NHS England has identified the Staffordshire clinical commissioning groups (CCGs) as high risk, and as such is monitoring their performance on a monthly basis with a full quarterly review of finance and performance. NHS England increases the intensity of performance reviews where there are significant shortfalls. This includes weekly meetings with CCGs where appropriate.</p><p> </p><p> </p><p> </p><p>Collaborative working relationships are a critical factor in securing sustainable services in any local health economy. The Commissioning Congress has been set up in Staffordshire to bring together both CCGs and local authority commissioners. The Congress will lead the Transformation Strategy which will drive the service redesign of the Staffordshire Health and Social Care economy to secure financial and clinically sustainable services in the long term. The Congress will engage with local providers in developing these plans to ensure that there is a single five-year plan for the local health economy. This work will lead to a full public consultation on those services during the autumn of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>The Congress brings together the combined skills, knowledge and expertise of commissioners to work the provider sector on defining the range, scale and scope of services changes to ensure Staffordshire is both clinically and financially sustainable in the long term.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL90 more like this
HL91 more like this
HL92 more like this
HL93 more like this
star this property question first answered
less than 2015-06-09T12:42:46.753Zmore like thismore than 2015-06-09T12:42:46.753Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this